MRVL Marvel Biosciences Corp.

0.0804USD0.1150 CAD · TSXV0.00%Mkt Cap: 5.92M USDP/E: —

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated d…

Key Statistics

Company
Market Cap5.92M USD
Enterprise Value5.74M USD
Revenue (TTM)—
Gross Profit-382.63K USD
Net Income (TTM)-1.55M USD
Revenue/Share—
Last Price0.0804 USD
Fiscal Year EndJul 2025
MR QuarterApr 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA57384M1077
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-2.67
EPS (TTM)-0.02 USD
EPS (Forward)—
52W Range
0.066413% of range0.1748
52W High0.1748 USD
52W Low0.0664 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE55.20%
ROA-676.88%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-804.13K USD
CapEx (TTM)—
FCF Margin—
FCF Yield-9.26%
Net Debt671.92K USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.58
Current Ratio0.18
Quick Ratio0.18
Book Value/Sh-0.03 USD
Cash/Share0.0049 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.73.68M
Float51.39M
Insiders19.09%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short3.39K
Short (prev mo.)7.45K
Technical
SMA 500.0889 (-9.6%)
SMA 2000.1051 (-23.5%)
Beta0.37
S&P 52W Chg12.00%
Avg Vol (30d)63.00K
Avg Vol (10d)54.78K
Technical Indicators
RSI (14)44.0
MACD-0.0006
MACD Signal-0.0013
MACD Hist.+0.0007
BB Upper0.0917 USD
BB Middle0.0839 USD
BB Lower0.0760 USD
BB Width18.73%
ATR (14)0.0066 USD
Vol Ratio (20d)3.13x

About Marvel Biosciences (CVE: MRVL)

›

Marvel Biosciences (CVE: MRVL) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.1150 CAD on 19 November 2026, down 36.1% over 52 weeks. Its 52-week range is 0.0950 CAD to 0.2500 CAD: the price is 54.0% below the high and 21.1% above the low.

Its market capitalisation is 8.47M CAD.

Marvel Biosciences reports return on equity of 55.2% and an operating margin of 0.0%.

Its debt exceeds its cash by 961.20K CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.